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ABSTRACT 
No single therapeutic agent has been recognized so far as the ultimate treatment for COVID-19 and many treatment strategies rely on associating 
different medications with proven or hypothetical anti-viral effects. Carvedilol is a third-generation beta-blocker displaying potential inhibitory 
properties on several key enzymatic processes and pathways involved in SARS-CoV-2 or other coronaviruses replication, in addition to the 
modulatory effect on several inflammatory messengers of COVID-19. These data could provide a reasonable hypothetical background for further 
investigating specific anti-SARS-CoV-2 effects and could pave the way for further clinical verification. 
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INTRODUCTION 
As global efforts are deployed to contain the novel coronavirus 
disease 2019 (COVID-19) pandemic, several candidate treatments 
are being used in clinical practice and/or tested in ongoing trials. 
Despite promising results, no single therapeutic agent has been 
identified as the ultimate treatment for severe acute respiratory 
syndrome coronavirus 2 (SARS-COV-2), and many protocols rely on 
associating different molecules with proven or putative anti-viral 
effects. Carvedilol is a non-specific ß-blocker indicated in congestive 
heart failure and hypertension, but additional anti-inflammatory and 
anti-oxidant properties and involvement in the regulation of various 
intracellular signaling pathways draw a distinctive pleiotropic 
profile for this cardiovascular agent [1-4]. While broncho-
constriction in asthmatic patients is a known side-effect of 
carvedilol, its specific impact on the intracellular pathways of the 
respiratory epithelial cell has not been fully addressed yet. Emerging 
data, however, shed light on new properties of carvedilol, allowing 
reasonable assumptions that, by acting on several cellular levels of 
SARS-CoV-2 and other similar coronaviruses, this agent could help 
control or mitigate the current COVID-19 pandemic.  
Hypothesis 
SARS-CoV-2 penetrates the cell after binding to angiotensin 
converting enzyme 2 (ACE 2), where the host cell proteases cleave 
certain viral proteins at low pH, resulting in the release of the viral 
genome into the  cytoplasm. Viral main proteases, including 3-
chymotrypsin-like protease (3CLpro), along with diverted 
intracellular enzymatic processes and pathways, including replicase-
transcriptase complex, mitogen-activated protein kinases (MAP-K) 
and ribososome machinery, are subsequently used in favour of the 
viral RNA transcription and protein synthesis. Following replication 
and assembly, the newly formed viral particles are transported to 
the cell surface in vesicles through the Golgi system before being 
released by exocytosis and infecting new host cells [5].  
Carvedilol has been shown to downregulate angiotensin converting 
enzyme expression [6], which shares substantial structural similarities 
with ACE 2. Although the specific effect of carvedilol on ACE2 is not 
well documented, we hypothesize that this agent could play an 
inhibitory role on several intracellular key levels of SARS-CoV-2 cycle. 
It could be indeed limiting coronavirus synthesis by increasing 
lysosomal pH [7]. By reducing p38 MAP-K activation, a ubiquitous 
conserved enzyme of eukaryote cells involved in promoting SARS-
CoV-2 intracellular synthesis, carvedilol may be additionally targeting 
the viral replication [2, 8, 9]. Moreover, carvedilol increases nitric 
oxide synthase activity and subsequently, nitric oxide levels, a 
molecule proven to inhibit the SARS-coronavirus replication cycle [10, 
11]. Furthermore, carvedilol was identified as a potential inhibitor of 
3-CLpro, the main SARS-CoV-2 protease, in a computational virtual 
three-dimensional molecular docking method, which retained few 
candidates out of the large ZINC U. S. Food and Drug Administration–
approved drug database [12]. 
In addition to the aforementioned mechanisms, recently identified 
beta1-adrenergic receptors (ß1AR) of the Golgi apparatus, 
intervening in viral transportation and exocytosis of newly formed 
viral particles, pave the way for investigating additional unsuspected 
properties of beta-blockers in this setting [13]. ß1AR stimulation, 
indeed, increases the production of cyclic adenosyl monophosphate 
(cAMP), a positive modulator of the exocytic pathway and, inversely, 
their inhibition correlates with decreased concentrations of cAMP 
and retarted Golgi exocytic viral trafficking [14, 15]. It can be fairly 
assumed that, by blocking these ß1AR, the cell-permeant agent 
carvedilol would reduce intercellular infectivity and viral 
propagation [13]. 
On another level, interleukin-6 (IL-6) holds a pivotal role in the 
inflammatory cascade of the severe and fatal cases of Covid-19 
infections and high levels of IL-6 seem to represent a predictive 
factor of respiratory failure [16, 17]. Angiotensin II (AgII) as well 
seems to correlate with viral load and degree of lung injury [18]. 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
ĸB) is another identified key player in the inflammatory signaling 
pathway of SARS-CoV infection and Covid-19 [19]. Inhibition of NF-
ĸB has been associated with reduced inflammation and increased 
survival in mice infected with SARS-CoV [17]. By down regulating IL-
6, AgII and NF-ĸB, carvedilol could be improving the outcome of 
patients with Covid-19 [4, 20, 21].  
Finally, cyclodextrins are enabling excipients, used in the 
pharmaceutical industry to enhance drug bioavailability. With 
additional cholesterol sequestering properties, these cyclic 
oligisaccharides cause lipid raft disruption and structural 
deformation of the viral envelope and cholesterol depletion of host 
cell membranes, hampering thereby fusion of the viral envelope 
with the cell membrane [22, 24]. Cyclodextrins have proven to 
reduce coronavirus infectivity and the development of cyclodextrin–
based delivery systems for carvedilol could provide this medication 
with additional anti-viral effects [25, 26]. 
The hypothesis that carvedilol exerts an anti-viral effect and a 
protective role in COVID-19 could be tested at several levels. The 
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possible inhibitory effect of carvedilol on viral replication and high 
titers could be studied in one or several cell lines of animal (Vero-
hSLAM, Vero E6†, Vero-CCL81, RK13) or human (Hep G2, HuH-7†, 
HAE) origin that support the SARS-CoV-2 replication [27]. Reduction 
in viral RNA titers with the addition of carvedilol could be first 
experimental evidence supporting an anti-viral activity in vitro. 
Case-control or retrospective cohort studies, comparing clinical 
outcomes and biological markers of patients taking carvedilol with 
the outcomes and markers in control groups, could serve as an 
epidemiological assessment of a possible protective role for this 
agent. At last, since carvedilol is a relatively safe medication with 
rare contraindications, positive results of an open-labeled 
prospective trial of this agent in patients having moderate to severe 
COVID-19 could pave the way for further randomized controlled 
trials. 
CONCLUSION 
Since the non-selective beta-blocker carvedilol potentially acts on 
several key levels of SARS-CoV-2 infection, including intracellular 
replication and exocytosis, in addition to modulating IL-6, AgII and 
NF-ĸB levels, we hypothesize that this commonly used 
antihypertensive agent might be a valuable addition to the COVID-19 
therapeutic armamentarium.  
OVERVIEW 
While the anti-oxidant and the anti-inflammatory properties and the 
protective effect of carvedilol in the setting of experimental viral 
infections are highlighted in several publications, possible specific 
anti-viral effects remain unaddressed. This paper provides a 
reasonable hypothetical background for investigating specific anti-
SARS-CoV-2 effects in vitro. Case-control or retrospective cohort 
studies could further help assess a possible protective role for this 
agent. Since carvedilol is a relatively safe medication with rare 
contraindications, positive results could pave the way for open-
labeled prospective studies and randomized controlled trials. 
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